Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.
Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R. Mantovani G, et al. Among authors: lusso mr. J Mol Med (Berl). 2003 Oct;81(10):664-73. doi: 10.1007/s00109-003-0476-1. Epub 2003 Aug 19. J Mol Med (Berl). 2003. PMID: 12928788
Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status.
Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Mulas C, Mudu MC, Murgia V, Camboni P, Massa E, Ferreli L, Contu P, Rinaldi A, Sanjust E, Atzei D, Elsener B. Mantovani G, et al. Among authors: lusso mr. Int J Cancer. 2002 Mar 1;98(1):84-91. doi: 10.1002/ijc.10143. Int J Cancer. 2002. PMID: 11857390 Free article.
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G, Macciò A, Madeddu C, Mulas C, Massa E, Astara G, Ferreli L, Mudu MC, Gramignano G, Murgia V, Lusso MR, Mocci M, Cardia A, Mura L. Mantovani G, et al. Among authors: lusso mr. Oncol Rep. 2002 Jul-Aug;9(4):887-96. Oncol Rep. 2002. PMID: 12066227 Clinical Trial.
The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression.
Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L, Mocci M, Massa E. Mantovani G, et al. Among authors: lusso mr. Free Radic Res. 2003 Feb;37(2):213-23. doi: 10.1080/10715760303849. Free Radic Res. 2003. PMID: 12653210
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
Mantovani G, Madeddu C, Gramignano G, Lusso MR, Mocci M, Massa E, Ferreli L, Astara G, Macciò A, Serpe R. Mantovani G, et al. Among authors: lusso mr. J Exp Ther Oncol. 2003 Jul-Aug;3(4):205-19. doi: 10.1046/j.1359-4117.2003.01096.x. J Exp Ther Oncol. 2003. PMID: 14567291 Clinical Trial.
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.
Mantovani G, Macciò A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L. Mantovani G, et al. Among authors: lusso mr. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1030-4. doi: 10.1158/1055-9965.EPI-05-0538. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16702388 Clinical Trial.
21 results